Key points from article :
DNA Nanobots, a leader in DNA nanoparticle design for targeted therapeutics, closed its pre-seed funding round to launch the BioPharma Partner Program.
They use DNA nanoparticles with custom antibodies to ferry medication precisely to desired tissues.
This tech tackles a major drug development hurdle: many drugs fail because they reach the wrong cells or deliver too little payload.
DNA Nanobots aims to solve this by delivering more drug to the right place.
BioPharma partners can use DNA Nanobots to improve their own drug pipelines.
Early results are promising- The company reports success in mouse studies and is collaborating with universities to push forward.
New funding round open and interested investors can connect with DNA Nanobots to discuss further investment.
The goal? Revolutionise drug development and delivery for a wider range of treatments.
